American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: Tamoxifen and raloxifene

Journal of Clinical Oncology

Volumn 17, Issue 6, 1999, Pages 1939-1955

  Chlebowski, Rowan T ^a   Collyar, Deborah E ^a   Somerfield, Mark R ^a   Pfister, David G ^a  

^a American Society of Clinical Oncology   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; CONJUGATED ESTROGEN; RALOXIFENE; TAMOXIFEN; TAMOXIFEN CITRATE;

ARTICLE; BONE DENSITY; BREAST CANCER; CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; CANCER SURVIVAL; ENDOMETRIUM CANCER; FEMALE; FRACTURE; HIGH RISK POPULATION; HOT FLUSH; HUMAN; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; RISK FACTOR; VAGINA DISCHARGE;

EID: 0033067832     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.6.1939     Document Type: Article

References (102)

1. Landis SH, Murray T, Bolden S, et al: Cancer statistics, 1999. CA Cancer J Clin 49:8-31, 1999
2. Fisher B, Costantino JP, Wickerham DL, et al: Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90:1371-1388, 1998
3. Tamoxifen prescribing information [package insert]. Wilmington, DE, Zeneca, 1998
4. Cummings SR, Norton L, Eckert S, et al: Raloxifene reduces risk of breast cancer and may decrease the risk of endometrial cancer in postmenopausal women: Two-year findings from the Multiple Outcomes of Raloxifene Evaluation (MORE) trial. Proc Am Soc Clin Oncol 17:2a, 1998 (abstr 3)
5. Jordan VC: Antiestrogen action of raloxifene and tamoxifene: Today and tomorrow. J Natl Cancer Inst 90:967-971, 1998
6. Jordan VC, Glusman JE, Eckert S, et al: Raloxifene reduces incident primary breast cancer: Integrated data from multicenter, double-blind, placebo-controlled, randomized trials in postmenopausal women. Breast Can Res Treat San Antonio Breast Cancer Symposium Proc 21:227, 1998 (abstr)
7. American Society of Clinical Oncology: Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. J Clin Oncol 14:2843-2877, 1996
8. American Society of Clinical Oncology: Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. J Clin Oncol 14:671-679, 1996
9. Powles T, Eeles R, Ashley S, et al: Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomized chemoprevention trial. Lancet 352:98-101, 1998
10. Veronesi U, Maisonneuve P, Costa A, et al: Prevention of breast cancer with tamoxifen: Preliminary findings from the Italian randomized trial among hysterectomized women. Lancet 352:93-97, 1998
11. Jordan VC, Glusman JE, Eckert S, et al: Incident primary breast cancers are reduced by raloxifene: Integrated data from multicenter, double blind, randomized trials in ∼12,000 postmenopausal women. Proc Am Soc Clin Oncol 17:122a, 1998 (abstr 466)
12. Osborne CK: Tamoxifen in the treatment of breast cancer. N Engl J Med 339:1609-1618, 1998
13. Anonymous: Tamoxifen for early breast cancer: An overview of the randomized trials - Early Breast Cancer Trialists' Collaborative Group. Lancet 351:1451-1467, 1998
14. Wolmark N, Dignam J, Fisher B: The addition of tamoxifen to lumpectomy and radiotherapy in the treatment of ductal carcinoma in situ (DCIS): Preliminary results of NSABP Protocol B-24. Breast Can Res Treat San Antonio Breast Cancer Symposium Proc 21:227, 1998 (abstr)
15. Fisher B, Costantino JP, Redmond CK, et al: A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 320:479-484, 1989
16. Rutqvist LE, Cedermark B, Glas U, et al: Contralateral primary tumors in breast cancer patients in a randomized trial of adjuvant tamoxifen therapy. J Natl Cancer Inst 83:1299-1306, 1991
17. Anonymous: Adjuvant tamoxifen in the management of operable breast cancer: The Scottish trial - Report from the Breast Cancer Trials Committee, Scottish Cancer Trials Office (MRC), Edinburgh. Lancet 2:171-175, 1987
18. Bondy ML, Lustbader ED, Halabi S, et al: Validation of a breast cancer risk assessment model in women with a positive family history. J Natl Cancer Inst 86:620-625, 1991
19. Gail MH, Brinton LA, Byar DP, et al: Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 81:1879-1886, 1989
20. Re: tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel P-1 study. J Natl Cancer Inst 91:730, 1999 (letter)
21. Veronesi U, Maisonneuve P, Costa A, et al: Drop-outs in tamoxifen prevention trials. Lancet 353:244, 1999 (letter)
22. Claus EB, Risch N, Thompson WD: Autosomal dominant inheritance of early-onset breast cancer: Implications for risk prediction. Cancer 73:643-651, 1994
23. Burke W, Daly M, Garber J, et al: Recommendations for follow-up care of individuals with an inherited predisposition to cancer: BRCA 1 and BRCA 2. JAMA 277:997-1003, 1997
24. Grann VR, Panageas KS, Whang W, et al: Decision analysis of prophylactic mastectomy and oophorectomy in BRCA1-positive or BRC42-positive patients. J Clin Oncol 16:979-985, 1998
25. Hartmann LC, Schaid DJ, Woods JE, et al: Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 340:77-84, 1999
26. Bruzzi P: Tamoxifen for the prevention of breast cancer: Important questions remain unanswered and existing trials should continue. Lancet 351:1428-1429, 1998
27. Pritchard KL: Is tamoxifen effective in prevention of breast cancer? Lancet 352:80-81, 1998
28. Karrison TG, Ferguson DJ, Meier P: Dormancy of mammary carcinoma after mastectomy. J Natl Cancer Inst 91:80-85, 1999
29. Delozier T, Switsers O, Genot JY, et al: Efficacy of delayed adjuvant tamoxifen (TAM) in early breast cancer: A multicenter randomized trial. Proc Am Soc Clin Oncol 12:47, 1993 (abstr 47)
30. Delozier T, Switzers O, Genot J, et al: Late delayed adjuvant tamoxifen in early breast cancer: Results of a cooperative randomized trial. Bull Cancer 84:25-30, 1997
31. Olsen MR, Love RR: Delayed "adjuvant" tamoxifen therapy in postmenopausal women: Ten-year results from the Wisconsin Tamoxifen Study. Proc Am Soc Clin Onc 17:118a, 1998 (abstr 453)
32. Assikis VJ, Jordan VC: Tamoxifen and Endometrial Cancer: The Worldwide Clinical Database. Melville, NY, PRR, Inc, 1998
33. Fisher B, Costantino JP, Redmond CK, et al: Endometrial cancer in tamoxifen-treated breast cancer patients: Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 86:527-537, 1994
34. McDonald CC, Alexander FE, Whyte BW, et al: Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomized trial: The Scottish Cancer Trials Breast Group. BMJ 311:977-980, 1995
35. Rutqvist LE, Johansson H, Signomklav T, et al: Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies: For the Stockholm Breast Cancer Study Group. J Natl Cancer Inst 87:645-651, 1995
36. Anonymous: ACOG committee opinion: Tamoxifen and endometrial cancer - Number 169, February 1996, Committee on Gynecologic Practice, American College of Obstetricians and Gynecologists. Int J Gynaecol Obstet 53:197-199, 1996
37. Berliere M, Charles A, Galant C, et al: Uterine side effects of tamoxifen: A need for systematic pretreatment screening. Obstet Gynecol 91:40-44, 1998
38. Neven P, Vergote I: Should tamoxifen users be screened for endometrial lesions? Lancet 351:155-157, 1998
39. Timmerman D, Deprest J, Bourne T, et al: Saline infusion sonography (SIS) or office hysteroscopy: Which is the best? A prospective randomized study. Eur J Cancer 34:S33-S34, 1998 (suppl 4)
40. Barakat RR: Endometrial cancer and tamoxifen. Primary Care Cancer 19:27-30, 1999
41. Assikis VJ, Neven P, Jordan VC, et al: A realistic clinical perspective of tamoxifen and endometrial carcinogenesis. Eur J Cancer 32A: 1464-1476, 1996
42. Powles TJ, Jones AL, Ashley SE, et al: The Royal Marsden Hospital pilot tamoxifen chemoprevention trial. Breast Cancer Res Treat 31:73-82, 1994
43. Love RR, Newcomb PA, Wiebe DA, et al: Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node-negative breast cancer. J Natl Cancer Inst 82:1327-1332, 1990
44. Rossner S, Wallgren A: Serum lipoproteins and proteins after breast cancer surgery and effects of tamoxifen. Atherosclerosis 52:339-346, 1984
45. Bilimoria MM, Jordan VC, Morrow M: Additional benefits of tamoxifen for postmeopausal patients, in Jordan VC (ed): Tamoxifen: A Guide for Clinicians and Patients. Huntington, NY, PRR, Inc, 1996, pp 75-89
46. Cattaneo M, Balietto L, Zighetti ML, et al: Tamoxifen reduces plasma homocysteine levels in healthy women. Br J Cancer 77:2264-2266, 1998
47. Costantino JP, Kuller LH, Ives DG, et al: Coronary heart disease mortality and adjuvant tamoxifen therapy. J Natl Cancer Inst 89:776-782, 1997
48. McDonald CC, Stewart HJ: Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial: The Scottish Breast Cancer Committee. BMJ 303:435-437, 1991
49. Rutqvist LE, Matteson A: Cardiac and thromboembolic morbidity among postmenopausal women with early-stage heart cancer in a randomized trial of adjuvant tamoxifen: The Stockholm Breast Cancer Study Group. J Natl Cancer Inst 85:1398-1406, 1993
50. Hulley S, Grady D, Bush T, et al: Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 280:605-613, 1998
51. Stampfer MJ, Coldity GA: Estrogen replacement therapy and coronary heart disease: A quantitative assessment of the epidemiological evidence. Prev Med 20:47-63, 1991
52. Petitti DB: Hormone replacement therapy and heart disease prevention: Experimentation trumps observation. JAMA 280:650-651, 1996
53. Eastell R: Treatment of postmenopausal osteoporosis. N Engl J Med 338:736-746, 1998
54. Magaziner J, Lydick E, Hawkes W: Excess mortality attributable to hip fracture in white women aged 70 years and older. Am J Public Health 87:1630-1636, 1997
55. Love RR, Barden HS, Mazess RB, et al: Effect of tamoxifen on lumbar spine bone mineral density in postmenopausal women after 5 years. Arch Intern Med 154:2585-2588, 1994
56. Phillips K, Glendon G, Knight JA: Putting the risk of breast cancer in perspective. N Engl J Med 340:141-143, 1999
57. Love RR, Mazess RB, Barden HS, et al: Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 326:852-856, 1992
58. Love RR, Mazess RB, Tormey DC, et al: Bone mineral density in women with breast cancer treated with adjuvant tamoxifen for at least two years. Breast Cancer Res Treat 12:297-302, 1998
59. Fornander T, Rutqvist LE, Sjoberg HE, et al: Long-term adjuvant tamoxifen in early breast cancer: Effect on bone mineral density in postmenopausal women. J Clin Oncol 8:1019-1024, 1990
60. Marttunen MB, Heitanen P, Tiitinen A, et al: Comparison of effects of tamoxifen and toremifene on bone biochemistry and bone mineral density in postmenopausal breast cancer patients. J Clin Endocrinol Metab 83:1158-1162, 1998
61. Powles TJ, Hickish T, Kanis JA, et al: Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 14:78-84, 1996
62. Godfredsen A, Christiansen C, Palshof T: The effect of tamoxifen on bone mineral content in premenopausal women with breast cancer. Cancer 53:853-857, 1984
63. Fentiman IS, Caleffi M, Rodin A, et al: Bone mineral content of women receiving tamoxifen for mastalgia. Br J Cancer 60:262-264, 1989
64. Cauley JA, Lucas FL, Kuller LH, et al: Bone mineral density and risk of breast cancer in older women: The study of osteoporotic fractures. JAMA 276:1404-1408, 1996
65. Zhang Y, Kiel DP, Kreger BE, et al: Bone mass and the risk of breast cancer among postmenopausal women. N Engl J Med 336:611-616, 1997
66. Daly E, Vessey MP, Hawkins MM, et al: Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 348:977-980, 1996
67. Jick H, Derby LE, Myers MW, et al: Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet 348:981-983, 1996
68. Pritchard KI, Paterson AH, Paul NA, et al: Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer: National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group. J Clin Oncol 14:2731-2737, 1996
69. Radloff LF: The CES-D Scale: A self report depression scale for research in the general public. Appl Psychol Meas 1:385-401, 1977
70. Ganz PA, Day R, Costantino IP: Compliance with quality of life data collection in the NSABP breast cancer prevention trial. Stat Med 17:613-622, 1998
71. Ganz PA, Day R, Ware JE, et al: Base-line quality of life assessment in the National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial. J Natl Cancer Inst 87:1372-1382, 1995
72. Baker VL, Draper M, Paul S, et al: Reproductive endocrine and endometrial effects of raloxifene hydrochloride, a selective estrogen receptor modulator, in women with regular menstrual cycles. J Clin Endocrinol Metab 83:6-13, 1998
73. Simpkins IW, Green PS, Gridley KE, et al: Role of estrogen replacement therapy in memory enhancement and prevention of neuronal loss associated with Alzheimer's disease. Am J Med 103:19S-25S, 1997
74. Tang MX, Jacobs D, Stern Y, et al: Effect of estrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet 348:429-432, 1996
75. Henderson V: Estrogen, cognition, and women's risk of Alzheimer's disease. Am J Med 03:11S-18S, 1997
76. Kawas C, Resnick S, Morrison A, et al: A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: The Baltimore Longitudinal Study of Aging. Neurology 48:1517-1521, 1997
77. Yaffe K, Sayawa G, Lieberfburg I, et al: Estrogen therapy in postmenopausal women: Effects on cognitive function and dementia. JAMA 279:688-695, 1988
78. Van Dam FS, Schagen SB, Muller MJ, et al: Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: High-dose versus standard-dose chemotherapy. I Natl Cancer Inst 90:210-218, 1998
79. The Women's Health Initiative Study Group: Design of the Women's Health Initiative clinical trial and observational study. Control Clin Trials 19:61-109, 1998
80. Vickers MR, Meade TW, Wilkes HC: Hormone replacement therapy and cardiovascular disease: The case for randomized controlled trial. CIBA Found Symp 16:150-158, 1995
81. De Backer G, De Bacquer D: Lifetime-risk prediction: A complicated business. Lancet 353:82-83, 1999
82. Chlebowski RT: Breast cancer chemoprevention: Tamoxifen -Current issues and future prospective. Cancer 72:1032-1037, 1993
83. Chlebowski RT, Lillington LB, Nelson A, et al: Barriers to minority/underserved breast cancer prevention study participation. Proc Am Soc Clin Oncol 11:A391, 1992 (abstr)
84. Raloxifene prescribing information [package insert]. Indianapolis, IN, Eli Lilly and Company, 1997
85. Khovidhunkit W, Shoback DM: Clinical effects of raloxifene hydrochloride in women. Ann Int Med 130:431-439, 1999
86. Jordan VC: Current approved uses of tamoxifen and recommendations in the United States, in Jordan VC (ed): Tamoxifen for the Treatment and Prevention of Breast Cancer. Melville, NY, PRR, Inc, 1998, pp 53-56
87. Buzdar AV, Marcus C, Holmes F, et al: Phase II evaluation of LY156758 in metastatic breast cancer. Oncology 45:344-345, 1988
88. Gradishar WJ, Glusman JE, Vogel CL, et al: Raloxifene HCI, a new endocrine agent, is active in estrogen receptor positive (ER+) metastatic breast cancer. Breast Can Res Treat San Antonio Breast Cancer Symposium Proc 20:53, 1997 (abstr)
89. Gottardis MM, Ricchio ME, Satyaswaroop PG, et al: Effect of steroidal and non-steriodal antiestrogens on the growth of a tamoxifen stimulated human endometrial carcinoma in athymic mice. Cancer Res 50:3189-3192, 1990
90. Delmas PD, Bjarnasan NG, Mitlak BH, et al: Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 337:1641-1647, 1997
91. Boss SM, Huster WJ, Neild JA, et al: Effects of raloxifene hydrochloride on the endometrium of postmenopausal women. Am J Obstet Gynecol 177:1458-1464, 1997
92. Barrret-Connor E, Wenger NK, Grady D, et al: Hormone and non-hormone therapy for the maintenance of postmenopausal health: The need for randomized controlled trials of estrogen and raloxifene. J Women's Health 7:839-847, 1998
93. Draper MW, Flowers DE, Huster WJ, et al: A controlled trial of raloxifene (LY139481) HCl: Impact on bone turnover and serum lipid profile in healthy postmenopausal women. J Bone Mineral Res 11:835-842, 1996
94. Walsh BW, Kuller LH, Wild RA, et al: Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA 279:1445-1485, 1998
95. Anonymous: Effects of hormone replacement therapy on endometrial histology in postmenopausal women: The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial - The Writing Group for the PEPI Trial. JAMA 275:370-375, 1996
96. Mijatovic V, Netelenbos C, van der Mooren MJ, et al: Randomized, double-blind placebo-controlled study of the effects of raloxifene and conjugated equine estrogen on plasma homocysteine levels in healthy postmenopausal women. Fertil Steril 70:1085-1089, 1998
97. Glusman J, Lu Y, Huster W, et al: Raloxifene effects on climacteric symptoms compared with hormone or estrogen replacement therapy (HRT or ERT). Proc North Am Menopause Soc, 8th Annual Meeting Program, 1997, p 65 (abstr)
98. Grodstein F, Stampfer MJ, Goldhaber SZ, et al: Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet 348:983-987, 1996
99. Smith BL, Gadd MA, Lawler C, et al: Perceptions of breast cancer risk among women in breast center and primary care settings: Correlation with age and family history of breast cancer. Surgery 120:297-303, 1996
100. Dolan NC, Lee AM, McDermott MM: Age-related differences in breast carcinoma knowledge, beliefs, and perceived risk among women visiting an academic general medicine practice. Cancer 80:413-420, 1997
101. Hebert-Croteau N, Goggin P, Kishchuk N: Estimation of breast cancer risk by women aged 40 and over: A population-based study. Can J Public Health 88:392-396, 1997
102. Kelsey JL, Horn-Ross PL: Breast cancer: Magnitude of the problem and descriptive epidemiology. Epidemiol Rev 15:7-16, 1993